Underlying hematological malignancy which is deemed as being potentially curable with allogeneic bone marrow or PBSC transplantation by the BMT voting team.
Hematological malignancies include, but are not limited to: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS. Patient should be in a partial (PR) or complete remission (CR) at the time of the transplant.
Existence of an HLA-matched or haploidentical relative who passes standard donor evaluations for bone marrow and kidney donation
LVEF \> 40% as measured by echocardiography or MUGA
FEV1, FVC, and DLCO \> 50% of predicted as measured by standard PFTs
Total bilirubin \< 2.0 (unless diagnosis of Gilbert's or hemolysis is made) and AST, ALT, alkaline phosphatase all \< 5x institutions upper limit of normal
ABO compatibility in the host vs. graft direction
Men and women of reproductive potential must agree to use a reliable method of birth control during the treatment, and women should do so for a period of 1 year following the transplant.
Participants should be on dialysis or have a CrCl ≤ 35 ml/min
Life expectancy greater than 6 months
Recipient ability to understand and provide informed consent
HLA matched or haploidentical relative as defined by 3/6, 4/6, or 5/6 HLA-matched at HLA -A, -B, or -DRB1 who is 18-70 years of age
ECOG performance status 0 or 1
Excellent health per conventional pre-donor history (medical and psychosocial evaluation)
• Acceptable laboratory parameters (hematology in normal or near-normal range; liver function \< 3 times the upper limit of normal and normal creatinine)
Compatible ABO blood group
Negative donor lymphocyte cross match
No positive testing for active viral infection (Hepatitis B, Hepatitis C, HIV)
Donor ability to understand and provide informed consent
Meets standard institutional criteria for both bone marrow or peripheral blood stem cell (PBSC) and kidney donation
You may not be if
Active serious infection
Participation in other investigational drug use at the time of enrollment
Positivity for active infection with HIV, HCV, or HBV
ABO blood group incompatibility in the host-vs-graft direction
Clareo Health | Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
